Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mCALR + CDK9 DAC
- Development stage
- Preclinical
- Lead developer
- Prelude Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
The mCALR + CDK9 DAC is an experimental degrader antibody conjugate (DAC) being developed by Prelude Therapeutics for the treatment of CALR-mutated myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and essential thrombocythemia (ET). This therapeutic modality combines a monoclonal antibody targeting the mutant calreticulin (CALR) neoantigen—found in approximately 25-35% of MF and ET patients—with a novel Cyclin-dependent kinase 9 (CDK9) protein degrader payload. The DAC is designed to selectively bind and internalize within CALR-mutant cells, where the degrader payload is released to induce the proteasomal degradation of CDK9. This mechanism selectively eliminates CALR-mutant MPN progenitor cells while sparing healthy CD34+ hematopoietic stem cells. Preclinical data presented at the 2025 American Society of Hematology (ASH) meeting supports its potential as a disease-modifying therapeutic for patients with CALR mutations.
- Other names
- mCALR-CDK9 DACmCALR-CDK-9 DACmCALR-CDK 9 DACmutant CALR-CDK9 degrader antibody conjugate
02
Targets
CALR mutant (Calreticulin Mutant Protein)CDK9 (Cyclin-dependent kinase 9)
Beyond the preview
Go deeper on mCALR + CDK9 DAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mCALR + CDK9 DAC.